Bullish case
$95 to $105
More likely if Medicaid HBR improvement continues, Marketplace losses normalize, Medicare PDP execution stays firm, 2026 guidance is raised again, and investors pay a high-teens multiple for restored earnings power.
Centene Corporation research snapshot
CNC AI Stock Analysis
CNC AI stock analysis currently reads Centene as a scaled government-sponsored managed care company recovering from a difficult 2025 Marketplace risk-pool reset. At the July 8, 2026 data cutoff, CNC traded near $66.12 with a verified market cap near $32.65 billion. Q1 2026 results showed better medical cost control, 5% premium and service revenue growth, and adjusted EPS guidance above $3.40, but the CNC AI stock forecast stays scenario-based because Medicaid rates, Marketplace acuity, policy changes, and benefit-cost ratios can move earnings quickly. This page is an information tool, not investment advice.
Current price
$66.12
Market cap
$32.65 billion verified market cap
AI score
58 / 100
Rating
Managed care recovery candidate with strong scale and policy-sensitive earnings risk
Trend status
Constructive short-term trend above key moving averages, but still dependent on medical-cost execution
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Centene has long public-company history, SEC filings, company earnings releases, StockAnalysis financials, Macrotrends history, balance-sheet data, proxy material, and broad healthcare policy coverage.
- bias Check
- The main AI bias risk is overreacting to the post-2025 rebound and treating one strong Q1 as a clean earnings reset. The counter-check is whether rate adequacy, Marketplace morbidity, Medicaid redeterminations, and policy pressure can again overwhelm scale benefits.
- ai Confidence
- High for FY2025 revenue, FY2025 GAAP loss, Q1 2026 premium and service revenue, share count, market-cap math, balance-sheet liquidity, debt, and moving-average references. Medium for forward earnings power because medical-cost trend, government rates, and ACA subsidy policy can change fast.
- investment Certainty
- Medium-low. The business has real scale and government-contract durability, but investment certainty is lower than data confidence because small medical-cost or rate errors can cause large EPS changes.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Centene runs Medicaid, Medicare, Commercial Marketplace, and related health programs for government-sponsored and under-insured populations at very large scale. | Medium-high |
| Moat | The moat comes from state contracts, local health-plan networks, claims infrastructure, regulatory know-how, and scale, but it is weaker than a consumer brand because contracts can be rebid and margins are regulated. | Medium |
| Management | CEO Sarah London has led since March 2022 and is trying to restore profitability after the 2025 Marketplace reset while narrowing the company around core health-plan operations. | Medium |
| Financial trend | FY2025 revenue rose to $194.8 billion while GAAP results swung to a $6.7 billion loss. Q1 2026 premium and service revenue rose 5% to $44.7 billion and adjusted EPS reached $3.37. | High |
| Valuation | Using $66.12, adjusted EPS guidance above $3.40, book value per share near $43.46, and FCF per share near $14.42, CNC screens near 19.45x adjusted EPS, 1.52x book, and 4.59x FCF. | Medium-high |
| Technical trend | The stock sits above 50-day and 200-day moving averages with neutral RSI, but resistance is close to the recent $69.29 high after a sharp 2026 rebound. | Medium |
| Risk level | Main risks are medical cost inflation, Medicaid rate lag, ACA subsidy changes, Marketplace morbidity, state contract losses, regulatory scrutiny, and execution after impairment charges. | High |
| AI confidence | Descriptive confidence is high because official filings and third-party data align. Forecast confidence is lower because policy and claims-cost variables are unstable. | High data confidence |
| Investment certainty | CNC is not a simple compounder. It is a recovery and execution case where the upside depends on rate adequacy and medical-cost control staying on track. | Medium-low |
CNC AI stock forecast
CNC AI Stock Forecast Scenarios
The CNC AI stock forecast uses the $66.12 price reference, management guidance above $3.40 in adjusted EPS, and a three-year scenario model. The audited model produced a bearish area near $28.80, a base area near $60.00, and a bullish area near $100.60 before any dividends. The wide spread reflects a business where earnings can recover quickly if cost trends normalize, but can also reset lower if policy or morbidity assumptions are wrong.
Base case
$56 to $64
More likely if adjusted EPS compounds in the high-single-digit range, revenue grows modestly, and the market values CNC near a mid-teens earnings multiple because policy risk remains visible.
Bearish case
$26 to $32
More likely if Marketplace morbidity worsens, Medicaid rates lag medical trend, ACA subsidy or state-contract changes pressure membership, and investors apply a single-digit earnings multiple.
CNC AI technical analysis
CNC AI Technical Analysis
CNC AI technical analysis is cautiously constructive as of the July 8, 2026 cutoff. StockAnalysis listed a July 7 close of $66.12, a 52-week range of $25.08 to $69.29, and volume near 4.17 million shares. Investing.com listed RSI near 48.92, a 50-day moving average near $65.92, and a 200-day moving average near $63.08. The useful framework is to separate a hold above the low-$60s from a failed breakout near the upper-$60s.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $66.12 | StockAnalysis close at July 7, 2026, used for market-cap and valuation checks. |
| Immediate support | $65 to $66 | This area overlaps the 50-day moving-average reference near $65.92 and the latest close. |
| Deeper support | $62 to $64 | This band brackets the 200-day moving-average reference near $63.08 and would test whether the 2026 recovery trend is still intact. |
| Near resistance | $68 to $70 | The recent 52-week high near $69.29 is the first breakout area bulls need to clear. |
| Moving averages | 50-day near $65.92, 200-day near $63.08 | Price is above both references, which supports the recovery trend but leaves little cushion if earnings commentary disappoints. |
| Momentum | RSI near 48.92 | Momentum is neutral rather than overheated, so the next earnings update matters more than a pure oscillator reading. |
| Volume | Recent volume near 4.17 million shares | Volume was below the 50-day average cited by market data reports, so a breakout needs stronger participation to confirm demand. |
| Volatility | Watch July 28, 2026 earnings | The next confirmed earnings date can reset the chart because HBR, Marketplace membership, and guidance carry high sensitivity. |
| Invalidation | Close below $62, then below $55 | A break below the 200-day area would weaken the trend. A move below the mid-$50s would argue the recovery trade is losing sponsorship. |
CNC AI trading strategy
CNC AI Trading Strategy Framework
The CNC AI trading strategy below is a rules-based research framework, not personal advice. It connects price behavior with Medicaid HBR, Marketplace membership, Medicare PDP execution, state rate updates, cash flow, debt reduction, and guidance language.
Trend-following setup
Watch for CNC to clear the $68 to $70 resistance band while Q2 results confirm stable HBR, better Marketplace economics, and adjusted EPS guidance at or above the Q1 update.
A failed breakout followed by a close below $62 should reduce trend confidence, especially if guidance language points to medical-cost pressure or weaker Marketplace risk adjustment.
Mean-reversion setup
If CNC pulls back toward the $56 to $64 base-case zone without a new policy or claims-cost shock, compare the lower price with contract scale, cash flow, book value, and debt reduction.
Do not treat a lower price as attractive if the pullback is tied to rate inadequacy, state contract losses, or another withdrawal of guidance.
Fundamental monitor
Track Medicaid HBR, Medicare HBR, Marketplace membership, ACA subsidy policy, total revenue guidance, adjusted EPS guidance, operating cash flow, total debt, and buyback activity.
Position sizing should reflect that CNC is a regulated healthcare payer with earnings leverage to assumptions, not a predictable software-style compounder.
Investment research summary
Four-master Research Compression
Business essence
Customers and governments pay Centene to administer health coverage for Medicaid, Medicare, Marketplace, and other populations that need access, provider networks, claims processing, compliance, and cost management.
Moat
The moat is strongest in state relationships, local plan operations, provider networks, regulated claims systems, data infrastructure, and scale. It is narrower than it looks if rates lag costs or if a state rebids contracts away from Centene.
Munger risk inversion
The thesis fails if medical costs outrun rates, if Marketplace morbidity again exceeds assumptions, if ACA subsidy rules reduce membership, if Medicaid redeterminations pressure volume, or if regulators and states demand lower margins.
Management
Sarah London has technology, strategy, and healthcare operating background and has led Centene since 2022. The key test is whether management can turn 2025 lessons into durable underwriting discipline without giving up too much growth.
Industry trend
Managed care benefits from government outsourcing, aging populations, and the need for cost control, but the industry is always tied to public budgets, benefit design, state procurement, medical inflation, and political scrutiny.
Valuation and margin of safety
At $66.12, the stock prices in a partial recovery rather than a full return to old earnings expectations. Margin of safety depends less on headline revenue growth and more on whether adjusted EPS above $3.40 becomes a durable floor.
Source-backed data
CNC Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CNC quote reference | $66.12 close on July 7, 2026 | StockAnalysis CNC quote | July 8, 2026 |
| Market cap and shares outstanding | $32.65 billion market cap, 493.80 million shares | StockAnalysis CNC statistics | July 8, 2026 |
| FY2025 total revenue | $194.777 billion | Centene FY2025 results release | July 8, 2026 |
| FY2025 GAAP net loss | $(6.674) billion | Macrotrends CNC net income | July 8, 2026 |
| Q1 2026 premium and service revenue | $44.655 billion, up 5% year over year | Centene Q1 2026 results release | July 8, 2026 |
| Q1 2026 adjusted EPS | $3.37, with 2026 adjusted diluted EPS guidance above $3.40 | Centene Q1 2026 results release | July 8, 2026 |
| Balance-sheet liquidity and debt | $23.741 billion cash and short-term investments, $16.4 billion total debt | Centene Q1 2026 balance sheet | July 8, 2026 |
| Technical references | RSI 48.917, 50-day MA $65.92, 200-day MA $63.08 | Investing.com CNC technical analysis | July 8, 2026 |
| Medicaid business position | Centene describes itself as the largest Medicaid managed care organization in the United States, with plans in 30 states | Centene Medicaid plans overview | July 8, 2026 |
| CEO background | Sarah London was appointed CEO effective March 22, 2022 | Centene CEO appointment release | July 8, 2026 |
Frequently Asked Questions
Explore the AI Stock PickerBuild an AI trading strategyRead the CAH AI stock analysisCompare BMY AI stock analysis
This CNC AI stock analysis is for informational and educational use only. It is not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenarios based on available public data as of the stated cutoff date and can be wrong if medical-cost trends, policy rules, company guidance, valuation multiples, or market conditions change.